gms | German Medical Science

GMDS 2012: 57. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V. (GMDS)

Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie

16. - 20.09.2012, Braunschweig

Personalized medicine using DNA biomarkers

Meeting Abstract

Search Medline for

  • Andreas Ziegler - Universität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Deutschland

GMDS 2012. 57. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS). Braunschweig, 16.-20.09.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12gmds144

DOI: 10.3205/12gmds144, URN: urn:nbn:de:0183-12gmds1449

Published: September 13, 2012

© 2012 Ziegler.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Biomarkers are of increasing importance for personalized medicine, including diagnosis, prognosis, and targeted therapy of a patient. Their use is extremely diverse, and it varies from pharmacodynamics to treatment monitoring. The particular features of DNA biomarkers, such as single nucleotide polymorphisms are discussed. Examples are provided for current use of DNA biomarkers in applications. Before a DNA biomarker or a set of DNA biomarkers is used in clinical routine for diagnosis, several phases of research need to be successfully passed. The phases for clinical trials for the validation of diagnostic and prognostic biomarkers are discussed in detail. Some DNA biomarkers and other biomarkers, such as DNA tumor biomarkers, are additionally intended to predict the likely response of a patient to a treatment in terms of efficacy and/or safety, and these are termed predictive biomarkers or, more generally, companion diagnostic tests. The final part of this article considers one specific clinical trial design for these biomarkers in detail.


References

1.
Ziegler A, Koch A, Krockenberger K, Großhennig A. Personalized Medicine Using DNA Biomarkers: A Review. Hum Genet. 2012, in press.